Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018059531) CRYSTAL FORM OF ADENOSINE A2A RECEPTOR ANTAGONIST DRUG AND PREPARATION METHOD AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/059531 International Application No.: PCT/CN2017/104218
Publication Date: 05.04.2018 International Filing Date: 29.09.2017
IPC:
C07D 417/12 (2006.01) ,A61K 31/454 (2006.01) ,A61P 25/28 (2006.01) ,A61P 25/36 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
4523
containing further heterocyclic ring systems
454
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
30
for treating abuse or dependence
36
Opioid-abuse
Applicants:
苏州晶云药物科技有限公司 CRYSTAL PHARMATECH CO., LTD. [CN/CN]; 中国江苏省苏州市 工业园区星湖街218号生物纳米园B4-101 B4-101, Biobay, 218 Xinghu Street, Industrial Park Suzhou, Jiangsu 215123, CN
Inventors:
陈敏华 CHEN, Minhua; CN
张炎锋 ZHANG, Yanfeng; CN
翟晓婷 ZHAI, Xiaoting; CN
鄢楷强 YAN, Kaiqiang; CN
张晓宇 ZHANG, Xiaoyu; CN
Agent:
北京林达刘知识产权代理事务所(普通合伙) LINDA LIU & PARTNERS; 中国北京市 东城区北三环东路36号北京环球贸易中心C座16层 F16 Tower C, Beijing Global Trade Center 36 North Third Ring East Road, Dongcheng District Beijing 100013, CN
Priority Data:
201610871979.930.09.2016CN
Title (EN) CRYSTAL FORM OF ADENOSINE A2A RECEPTOR ANTAGONIST DRUG AND PREPARATION METHOD AND USE THEREOF
(FR) FORME CRISTALLINE D'UN MÉDICAMENT ANTAGONISTE DU RÉCEPTEUR DE L'ADÉNOSINE A 2A , SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
(ZH) 一种腺苷A2A受体拮抗剂药物的晶型及其制备方法和用途
Abstract:
(EN) A crystal form of an adenosine A2A receptor antagonist drug, tozadenant, and a preparation method and use thereof. The prepared tozadenant has crystal form CS1, can be used to prepare an adenosine A2A receptor antagonist drug formulation, provides a new option for the preparation of a drug formulation containing tozadenant, and has a crucial value for drug development.
(FR) L'invention concerne une forme cristalline d'un médicament antagoniste du récepteur de l'adénosine A 2A , un tozadenant, son procédé de préparation et son utilisation. Le tozadenant préparé a une forme cristalline CS1, peut être utilisé pour préparer une formulation de médicament antagoniste du récepteur de l'adénosine A 2A , fournit une nouvelle option pour la préparation d'une formulation de médicament contenant du tozadenant, et a une valeur cruciale pour le développement du médicament.
(ZH) 一种腺苷A2A受体拮抗剂药物(Tozadenant) 的晶型及其制备方法和用途。制备得到的Tozadenant的晶型为晶型CS1,可用于制备腺苷A2A受体拮抗剂药物制剂,为含Tozadenant的药物制剂的制备提供了新的选择,对于药物开发具有非常重要的价值。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)